详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts

17| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, China [2]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany [3]Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany [4]Department of Old Age Psychiatry and Cognitive Disorders, University of Bonn Medical Center, Bonn, Germany [5]German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany [6]Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany [7]Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Humboldt-Universität zu Berlin, Berlin, Germany [8]Clinical Functional Imaging Group, Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany [9]Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany [10]Department of Diagnostic and Interventional Radiology and NuclearMedicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany [11]German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany [12]Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany [13]German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany [14]Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von- Guericke University,Magdeburg, Germany [15]Department of clinical biobank, XuanWu Hospital of Capital Medical University, Beijing, China [16]Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China [17]Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany [18]Department of Neurology, Beijing ChaoYang Hospital of Capital Medical University, Beijing, China [19]Department of Radiology and Nuclear Medicine, XuanWu Hospital of Capital Medical University, Beijing, China [20]Department of NuclearMedicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany [21]Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Jülich, Germany [22]Department of NuclearMedicine, University Hospital Bonn, Bonn, Germany [23]Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany [24]School of Information and Communication Engineering, Hainan University, Haikou, China [25]German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany [26]Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany [27]Department of NuclearMedicine, Rostock University Medical Centre, Rostock, Germany [28]Tsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen, China [29]German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany [30]Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany [31]Department of Neurology, Tangshan Central Hospital, Tanshan, China [32]Medical Imaging Department of Hainan Cancer Hospital, Haikou, China [33]Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany [34]Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany [35]Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany [36]Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK [37]University of Edinburgh and UK DRI, Edinburgh, UK [38]School of Medicine, Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany [39]Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Köln, Germany [40]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Köln, Germany [41]Department of Psychiatry & Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, San Antonio, Texas, USA [42]Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK [43]Department of Neuroradiology, University Hospital LMU,Munich, Germany [44]Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard- Karls-University, Tuebingen, Germany [45]Department of Nuclear Medicine, Ludwig-Maximilian-University Munich, Munich, Germany [46]Department of NuclearMedicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland [47]Department of Neurology, University of Bonn, Bonn, Germany [48]German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany [49]Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal [50]School of Biomedical Engineering, Hainan University, Haikou, China [51]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China [52]National Clinical Research Center for Geriatric Disorders, Beijing, China [53]The Central Hospital of Karamay, Xinjiang, China

出处：

DOI：

ISSN：

关键词： amyloid pathology cognitive decline cross-cultural study longitudinal design PET plasma Aβ42/40 ratio Stage 2 Alzheimer’s disease subjective cognitive decline

摘要：

Subjective cognitive decline (SCD) in amyloid-positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies.Eight hundred twenty-one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed-effects models.In the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive decline or diminished practice effects compared with NC or Aβ- participants with SCD. These findings were confirmed using different operationalizations of SCD and amyloid positivity, and across different SCD recruitment settings.Aβ+ individuals with SCD in German and Chinese populations showed greater global cognitive decline and could be targeted for interventional trials.SCD in amyloid-positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区临床神经病学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区临床神经病学

JCR分区：

出版当年[2022]版：

Q1 CLINICAL NEUROLOGY

最新[2023]版：

Q1 CLINICAL NEUROLOGY

影响因子： 13.1 最新[2023版] 16.1 最新五年平均 14 出版当年[2022版] 18 出版当年五年平均 16.655 出版前一年[2021版] 13.1 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, China [2]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany [3]Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany

通讯作者：

通讯机构： [1]Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, China [16]Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China [50]School of Biomedical Engineering, Hainan University, Haikou, China [51]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China [52]National Clinical Research Center for Geriatric Disorders, Beijing, China [53]The Central Hospital of Karamay, Xinjiang, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts

文献详情

相关文献